Latest News and Press Releases

EXTON, PA, April 14, 2025 (GLOBE NEWSWIRE) -- Johnson & Johnson’s recent announcement of positive Phase 3 data for its oral IL-23 receptor antagonist, icotrokinra (JNJ-2113), has sparked notable...

EXTON, PA, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The FDA's approval of Eli Lilly’s Omvoh for Crohn’s disease marks a significant milestone as the therapy becomes the second IL-23 inhibitor available for...

EXTON, PA, Oct. 01, 2024 (GLOBE NEWSWIRE) -- The past twelve months have been transformative for the rapidly evolving ulcerative colitis (UC) market, with a surge in advanced therapies receiving FDA...

Asbestos Contamination in Everyday Talc Fuels Alarm and Health Concerns Among U.S. Women

Hyderabad, March 31, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled "Pain Management Market - (2023 – 2028),” the market is expected to register a CAGR of 7.39%. The...

Portland, OR, Nov. 27, 2022 (GLOBE NEWSWIRE) -- A new business intelligence report released by Allied Market Research, the global Flow Diverters Market generated $251.50 million in 2021, and is...

FRAMINGHAM, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...

FRAMINGHAM, Mass., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...

FRAMINGHAM, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...

FRAMINGHAM, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...